Basics Zymeworks Inc. Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. IPO Date: April 28, 2017 Sector: Healthcare Industry: Biotech Market Cap: $781.85M Activated in VL: True Average Daily Range Avg Daily Range: $0.46 | 2.64% Avg Daily Range (30 D): $0.26 | 2.22% Avg Daily Range (90 D): $0.32 | 2.54% Institutional Daily Volume Avg Daily Volume: .43M Avg Daily Volume (30 D): .37M Avg Daily Volume (90 D): .46M Trade Size Avg Trade Size (Sh.): 106 Avg Trade Size (Sh.) (30 D): 55 Avg Trade Size (Sh.) (90 D): 65 Institutional Trades Total Inst.Trades: 1,424 Avg Inst. Trade: $1.74M Avg Inst. Trade (30 D): $.99M Avg Inst. Trade (90 D): $1.08M Avg Inst. Trade Volume: .12M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.33M Avg Closing Trade (30 D): $.99M Avg Closing Trade (90 D): $1.11M Avg Closing Volume: 106.05K         News May 30, 2025 @ 10:00 AM Zymeworks Announces NMPA Approval of Zanidatamab i... Source: N/A May 22, 2025 @ 9:00 PM Zymeworks Announces Presentations Highlighting Bre... Source: Zymeworks Inc. May 21, 2025 @ 10:00 AM Zymeworks Announces Participation in Upcoming Inve... Source: N/A Apr 17, 2025 @ 10:00 AM Zymeworks to Report First Quarter 2025 Financial R... Source: N/A Feb 26, 2025 @ 11:00 AM Zymeworks Announces Achievement of $14 Million Mil... Source: N/A Financials   TTM Q4 2024 FY 2024 Basic EPS $-.3 $-.32 $-1.62 Diluted EPS $-.3 $-.32 $-1.62 Revenue $ 27.11M $ 31.03M $ 76.3M Gross Profit $ $ $ Net Income / Loss $ -22.64M $ -23.51M $ -122.7M Operating Income / Loss $ -25.61M $ -22.22M $ -137.11M Cost of Revenue $ $ $ Net Cash Flow $ 10.1M $ -56.25M $ -91.45M PE Ratio